Loading...

Genprex

DB:2DE
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2DE
DB
$28M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Genprex, Inc. operates as a clinical-stage gene therapy company. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
2DE Share Price and Events
7 Day Returns
-0.1%
DB:2DE
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-
DB:2DE
-5.6%
DE Biotechs
-4.5%
DE Market
2DE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genprex (2DE) -0.1% -2.3% 16.7% - - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • No trading data on 2DE.
  • No trading data on 2DE.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

2DE Value

 Is Genprex undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Genprex. This is due to cash flow or dividend data being unavailable. The share price is €1.564.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genprex's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genprex's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2DE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.90
NasdaqCM:GNPX Share Price ** NasdaqCM (2019-04-25) in USD $1.8
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genprex.

DB:2DE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:GNPX Share Price ÷ EPS (both in USD)

= 1.8 ÷ -0.90

-2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genprex is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Genprex is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Genprex's expected growth come at a high price?
Raw Data
DB:2DE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
20.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genprex, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genprex's assets?
Raw Data
DB:2DE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.58
NasdaqCM:GNPX Share Price * NasdaqCM (2019-04-25) in USD $1.8
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:2DE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:GNPX Share Price ÷ Book Value per Share (both in USD)

= 1.8 ÷ 0.58

3.09x

* Primary Listing of Genprex.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genprex is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Genprex's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Genprex has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2DE Future Performance

 How is Genprex expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genprex expected to grow at an attractive rate?
  • Genprex's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Genprex's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Genprex's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2DE Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2DE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 20.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2DE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2DE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 51 18 1
2022-12-31 0 -22 1
2021-12-31 0 -21 1
2020-12-31 0 -21 1
2019-12-31 0 -16 1
DB:2DE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -7 -12
2018-09-30 -5 -10
2018-06-30 -4 -8
2018-03-31 -2 -3
2017-12-31 -2 -3
2017-09-30 -3 -4
2017-06-30 -2 -4
2017-03-31 -2 -5
2016-12-31 -1 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genprex's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Genprex is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2DE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Genprex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2DE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.76 0.76 0.76 1.00
2022-12-31 -0.93 -0.93 -0.93 1.00
2021-12-31 -0.92 -0.92 -0.92 1.00
2020-12-31 -1.02 -1.02 -1.02 1.00
2019-12-31 -0.83 -0.83 -0.83 1.00
DB:2DE Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.90
2018-09-30 -0.75
2018-06-30 -0.67
2018-03-31 -0.28
2017-12-31 -0.29
2017-09-30 -0.20
2017-06-30 -0.24
2017-03-31 -0.35
2016-12-31 -0.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Genprex will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Genprex's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genprex has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2DE Past Performance

  How has Genprex performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genprex's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genprex does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Genprex's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Genprex's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Genprex's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genprex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2DE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -12.37 11.39 0.97
2018-09-30 -9.61 8.86 0.72
2018-06-30 -8.14 7.82 0.28
2018-03-31 -3.26 2.97 0.27
2017-12-31 -3.31 3.02 0.29
2017-09-30 -3.65 3.29 0.36
2017-06-30 -3.65 3.26 0.39
2017-03-31 -4.56 4.19 0.37
2016-12-31 -4.13 3.78 0.35
2015-12-31 -1.07 0.87 0.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Genprex has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Genprex has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Genprex improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Genprex's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genprex has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2DE Health

 How is Genprex's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genprex's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genprex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genprex has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genprex's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Genprex has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genprex Company Filings, last reported 3 months ago.

DB:2DE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 8.88 0.00 8.60
2018-09-30 10.48 0.00 10.31
2018-06-30 12.59 0.00 12.00
2018-03-31 -0.04 0.28 0.02
2017-12-31 0.43 0.00 0.16
2017-09-30 0.87 0.00 0.37
2017-06-30 0.80 0.00 0.47
2017-03-31 1.11 0.00 0.93
2016-12-31 1.62 0.00 1.60
2015-12-31 0.39 0.00 0.23
  • Genprex has no debt.
  • Genprex currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Genprex has sufficient cash runway for 1.2 years based on current free cash flow.
  • Genprex has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 60.5% each year.
X
Financial health checks
We assess Genprex's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genprex has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2DE Dividends

 What is Genprex's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genprex dividends.
If you bought €2,000 of Genprex shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genprex's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genprex's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2DE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2DE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genprex has not reported any payouts.
  • Unable to verify if Genprex's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genprex's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genprex has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genprex's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genprex afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genprex has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2DE Management

 What is the CEO of Genprex's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Varner
COMPENSATION $334,069
AGE 61
TENURE AS CEO 6.7 years
CEO Bio

Mr. John Rodney Varner is a co-founder of Genprex, Inc. and has been the Chief Executive Officer, Secretary and Chairman of the Board of Genprex, Inc. since August 2012. He served as President at Genprex, Inc. since August 2012 until April 10, 2018. Mr. Varner has more than thirty-three years of legal experience with large and small law firms and as outside general counsel of a NASDAQ traded company. He represents for-profit and non-profit companies at the Board of Directors or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers, licensing, collaboration and research agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues and real estate matters. He serves as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for Fifth Circuit and the United States Tax Court. He is a registered securities representative and owner of a company that is a licensed securities broker-dealer. He maintains Series 7, 24, 63 and 79 securities registrations. He is a member of the Board of Directors of Texas Healthcare and Bioscience Institute (THBI), and serves as its General Counsel. He is also a founder and member of the Board of Directors of Texas Medical Device Alliance. He holds J.D. from University of Texas School of Law in 1978 and holds BBA with high honors from Texas A & M University in 1976.

CEO Compensation
  • John's compensation has been consistent with company performance over the past year.
  • John's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Genprex management team in years:

2.6
Average Tenure
41
Average Age
  • The tenure for the Genprex management team is about average.
Management Team

John Varner

TITLE
Co-Founder
COMPENSATION
$334K
AGE
61
TENURE
6.7 yrs

Julien Pham

TITLE
President & COO
COMPENSATION
$302K
AGE
41
TENURE
1 yrs

Ryan Confer

TITLE
Chief Financial Officer
COMPENSATION
$585K
AGE
36
TENURE
2.6 yrs

Jack Roth

TITLE
Chairman of Scientific & Medical Advisory Board
Board of Directors Tenure

Average tenure and age of the Genprex board of directors in years:

6.7
Average Tenure
59
Average Age
  • The tenure for the Genprex board of directors is about average.
Board of Directors

John Varner

TITLE
Co-Founder
COMPENSATION
$334K
AGE
61
TENURE
6.7 yrs

David Friedman

TITLE
Director
COMPENSATION
$191K
AGE
54
TENURE
6.7 yrs

Bob Pearson

TITLE
Director
COMPENSATION
$191K
AGE
55
TENURE
6.8 yrs

Jack Roth

TITLE
Chairman of Scientific & Medical Advisory Board

Jim Rothman

TITLE
Strategic Advisor to the Board of Directors
AGE
67
TENURE
6.8 yrs

Pasi Janne

TITLE
Member of Scientific & Medical Advisory Board

Tony Mok

TITLE
Member of Scientific & Medical Advisory Board
AGE
57

George Simon

TITLE
Member of Scientific & Medical Advisory Board

John Bonfiglio

TITLE
Director
AGE
64
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
02. Aug 18 Buy Julien Pham Individual 30. Jul 18 30. Jul 18 500 €2.90 €1,451
X
Management checks
We assess Genprex's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genprex has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2DE News

Simply Wall St News

2DE Company Info

Description

Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.

Details
Name: Genprex, Inc.
2DE
Exchange: DB
Founded: 2009
$25,108,034
15,536,765
Website: http://www.genprex.com
Address: Genprex, Inc.
Health Discovery Building,
1601 Trinity Street,
Austin,
Texas, 78712,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM GNPX Voting Common Stock Nasdaq Capital Market US USD 29. Mar 2018
DB 2DE Voting Common Stock Deutsche Boerse AG DE EUR 29. Mar 2018
Number of employees
Current staff
Staff numbers
7
Genprex employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 23:20
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/01
Last earnings filing: 2019/04/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.